Next-generation sequencing in liquid biopsy: cancer screening and early detection

[1]  B. Vincenzi,et al.  Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples , 2020, Journal of experimental & clinical cancer research : CR.

[2]  W. Kim,et al.  Current status and future perspectives of liquid biopsy in non-small cell lung cancer , 2020, Journal of pathology and translational medicine.

[3]  E. Prochownik,et al.  Sequential analysis of transcript expression patterns improves survival prediction in multiple cancers , 2020, BMC Cancer.

[4]  Tao Xu,et al.  Liquid Biopsy Applications in the Clinic , 2020, Molecular Diagnosis & Therapy.

[5]  G. Pentheroudakis,et al.  Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat? , 2019, Cancers.

[6]  J. McPherson,et al.  Sensitive tumour detection and classification using plasma cell-free DNA methylomes , 2018, Nature.

[7]  G. Song,et al.  Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing , 2018, Molecular Cancer.

[8]  F. Basolo,et al.  Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma , 2018, Head & neck.

[9]  P. Guan,et al.  Circulating Tumor DNA Assays in Clinical Cancer Research , 2018, Journal of the National Cancer Institute.

[10]  N. Nguyen,et al.  Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. , 2018, Lab on a chip.

[11]  C. Sotiriou,et al.  Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor , 2018, Oncotarget.

[12]  Alison S. Devonshire,et al.  Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA , 2018, PloS one.

[13]  Jun Wang,et al.  Role of circulating tumor DNA in the management of early‐stage lung cancer , 2018, Thoracic cancer.

[14]  S. Kelley,et al.  Single Cell mRNA Cytometry via Sequence-Specific Nanoparticle Clustering and Trapping , 2018, Nature Chemistry.

[15]  Maximilian Diehn,et al.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Archives of pathology & laboratory medicine.

[16]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[17]  Wenxin Qin,et al.  Exosomes as a liquid biopsy for lung cancer. , 2018, Lung cancer.

[18]  B. Park,et al.  Circulating Tumor DNA: Measurement and Clinical Utility. , 2018, Annual review of medicine.

[19]  Abhijit A. Patel,et al.  Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA , 2018, Clinical Cancer Research.

[20]  A. Bardelli,et al.  Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  C. Noehammer,et al.  Multiplexed and Sensitive DNA Methylation Testing Using Methylation-Sensitive Restriction Enzymes "MSRE-qPCR". , 2018, Methods in molecular biology.

[22]  O. Elemento,et al.  Challenges in Using ctDNA to Achieve Early Detection of Cancer , 2017, bioRxiv.

[23]  K. Grankvist,et al.  Liquid biopsies in lung cancer-time to implement research technologies in routine care? , 2017, Annals of translational medicine.

[24]  M. Nykter,et al.  Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer , 2017, Journal of the National Cancer Institute.

[25]  Qi Zhao,et al.  Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. , 2017, Nature materials.

[26]  M. Makary,et al.  Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers , 2017, Proceedings of the National Academy of Sciences.

[27]  Jianjun He,et al.  Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker , 2017, Oncotarget.

[28]  Sam Angiuoli,et al.  Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.

[29]  G. Lyman,et al.  Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology , 2017, JAMA oncology.

[30]  K. Hekmat,et al.  „Liquid biopsy“ , 2017, Der Chirurg.

[31]  Lianghong Zheng,et al.  DNA methylation markers for diagnosis and prognosis of common cancers , 2017, Proceedings of the National Academy of Sciences.

[32]  Jia Jia,et al.  The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis , 2017, Scientific Reports.

[33]  Jun Wang,et al.  Comparison of plasma to tissue DNA mutations in surgical patients with non–small cell lung cancer , 2017, The Journal of thoracic and cardiovascular surgery.

[34]  P. V. Van Schil,et al.  Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. , 2017, Lung cancer.

[35]  Ashwini Naik,et al.  Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.

[36]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[37]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[38]  Kang Zhang,et al.  Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA , 2017, Nature Genetics.

[39]  Dorota Kwapisz,et al.  The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? , 2017, Annals of translational medicine.

[40]  M. Francl.  Making molecular monsters. , 2017, Nature chemistry.

[41]  S. Merajver,et al.  Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. , 2016, Clinical biochemistry.

[42]  M. Provencio,et al.  Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. , 2016, Translational lung cancer research.

[43]  C. Paweletz,et al.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Yang Liu,et al.  Circulating tumor DNA detection in lung cancer patients before and after surgery , 2016, Scientific Reports.

[45]  M. Raffeld,et al.  Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma , 2016, Clinical Cancer Research.

[46]  T. Haferlach,et al.  Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia , 2016, Haematologica.

[47]  Ash A. Alizadeh,et al.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.

[48]  G. Sölétormos,et al.  Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer , 2016, Clinical Epigenetics.

[49]  Henrik Zetterberg,et al.  Identification of tissue-specific cell death using methylation patterns of circulating DNA , 2016, Proceedings of the National Academy of Sciences.

[50]  Ash A. Alizadeh,et al.  Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.

[51]  K. Fitch,et al.  Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service. , 2016, American health & drug benefits.

[52]  A. Nakorchevsky,et al.  Ultrasensitive Detection of Multiplexed Somatic Mutations Using MALDI-TOF Mass Spectrometry. , 2016, The Journal of molecular diagnostics : JMD.

[53]  M. Speicher,et al.  mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA. , 2016, Advances in experimental medicine and biology.

[54]  J. Herman,et al.  DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies , 2015, Nucleic acids research.

[55]  R. Strausberg,et al.  Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  Allison Hills,et al.  Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. , 2015, Clinical chemistry.

[57]  Peter Ulz,et al.  Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach. , 2015, Clinical chemistry.

[58]  I. Bièche,et al.  Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.

[59]  H. Nielsen,et al.  Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery , 2015, Gut.

[60]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[61]  Lele Song,et al.  SEPT9: A Specific Circulating Biomarker for Colorectal Cancer. , 2015, Advances in clinical chemistry.

[62]  S Michiels,et al.  Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  R. McCormack,et al.  Gefitinib Treatment in EGFR Mutated Caucasian NSCLC , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[64]  Olivier Elemento,et al.  Double-stranded DNA in exosomes: a novel biomarker in cancer detection , 2014, Cell Research.

[65]  Yusuke Yoshioka,et al.  Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen , 2014, Nature Communications.

[66]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[67]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[68]  H. Cao,et al.  High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[69]  R. McCormack,et al.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study , 2013, British Journal of Cancer.

[70]  K. Pantel,et al.  Real-time liquid biopsy in cancer patients: fact or fiction? , 2013, Cancer research.

[71]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[72]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[73]  Thomas Rösch,et al.  Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer , 2013, Gut.

[74]  O. Tangvarasittichai,et al.  The Plasma DNA Concentration as a Potential Breast Cancer Screening Marker , 2013, Indian Journal of Clinical Biochemistry.

[75]  T. Szemeš,et al.  Fragmentation of DNA affects the accuracy of the DNA quantitation by the commonly used methods , 2013, Biological Procedures Online.

[76]  G. Parmigiani,et al.  Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.

[77]  K. Kinzler,et al.  FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing , 2012, PloS one.

[78]  Torunn I Yock,et al.  Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. , 2012, Cancer research.

[79]  M. Ferrari,et al.  Temperature-tolerant COLD-PCR reduces temperature stringency and enables robust mutation enrichment. , 2012, Clinical chemistry.

[80]  N. Rosenfeld,et al.  Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.

[81]  Stephan Beck,et al.  Methylome analysis using MeDIP-seq with low DNA concentrations , 2012, Nature Protocols.

[82]  L. Tanoue,et al.  Reduced lung cancer mortality with low-dose computed tomographic screening , 2011 .

[83]  M. Ferrari,et al.  Temperature-Tolerant COLD-PCR Eliminates Temperature Stringency and Enables Robust Mutation Enrichment , 2012 .

[84]  E. Mclean,et al.  Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR , 2011, PloS one.

[85]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[86]  K. Kinzler,et al.  Detection and quantification of rare mutations with massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[87]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[88]  C. Earle,et al.  Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[89]  M. Ychou,et al.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts , 2010, Nucleic acids research.

[90]  Francisco M. De La Vega,et al.  Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2010, Science Translational Medicine.

[91]  G. Daley,et al.  Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming , 2009, Nature Biotechnology.

[92]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[93]  Dong Xu,et al.  Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. , 2007, Cancer research.

[94]  Tian-Li Wang,et al.  Digital karyotyping , 2002, Nature Protocols.

[95]  F. Clavel-Chapelon,et al.  TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. , 2006, Cancer research.

[96]  Wei Jiang,et al.  High-throughput DNA methylation profiling using universal bead arrays. , 2006, Genome research.

[97]  A. Gnirke,et al.  Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis , 2005, Nucleic acids research.

[98]  G. Riggins,et al.  Genomic amplification of orthodenticle homologue 2 in medulloblastomas. , 2005, Cancer research.

[99]  R. Chiu,et al.  EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. , 2004, Clinical chemistry.

[100]  D. Dressman,et al.  Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[101]  Bruno Landi,et al.  Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis , 2002, International journal of cancer.

[102]  M. Stroun,et al.  About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[103]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[104]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[105]  R. Hruban,et al.  Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. , 1994, Cancer research.

[106]  W. Couldwell.  CLINICAL STUDIES , 2022 .